These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9107273)

  • 1. Hormone replacement therapy and high incidence of breast cancer between mammographic screens.
    Beral V; Banks E; Reeves G; Wallis M
    Lancet; 1997 Apr; 349(9058):1103-4. PubMed ID: 9107273
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is estrogen therapy of significance for the incidence of breast cancer?].
    Bakken K
    Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2801; author reply 2801. PubMed ID: 15534689
    [No Abstract]   [Full Text] [Related]  

  • 3. Mammographic density, hormone therapy, and risk of breast cancer.
    Ursin G; Pike M
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1750; author reply 1750. PubMed ID: 16985042
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Robbins AS; Clarke CA
    J Natl Cancer Inst; 2007 Dec; 99(23):1815; author reply 1816-7. PubMed ID: 18042938
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast cancer decline mirrors fall in hormone use, spurs both debate and research.
    McNeil C
    J Natl Cancer Inst; 2007 Feb; 99(4):266-7. PubMed ID: 17312300
    [No Abstract]   [Full Text] [Related]  

  • 6. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer?
    Yaffe M; Hendrix S; Pike M; Santen R; Eden J; Genazzani A
    Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():17-21. PubMed ID: 16112951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Vaidya JS
    J Natl Cancer Inst; 2008 Apr; 100(8):598-9; author reply 599. PubMed ID: 18398100
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pronounced differences in the estimation of breast cancer mortality in connection with hormone replacement therapy and mammographic screening].
    Jørgensen KJ
    Ugeskr Laeger; 2004 Apr; 166(15-16):1465. PubMed ID: 15146820
    [No Abstract]   [Full Text] [Related]  

  • 9. Breast cancer incidence and use of hormone therapy in Denmark 1978-2007.
    von Euler-Chelpin M
    Cancer Causes Control; 2011 Feb; 22(2):181-7. PubMed ID: 21103920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.
    Rosenberg RD; Hunt WC; Williamson MR; Gilliland FD; Wiest PW; Kelsey CA; Key CR; Linver MN
    Radiology; 1998 Nov; 209(2):511-8. PubMed ID: 9807581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy and high incidence of breast cancer between mammographic screens.
    Schouten LJ; de Rijke JM; Schlangen JT; Verbeek AL
    Lancet; 1997 Apr; 349(9058):1104. PubMed ID: 9107274
    [No Abstract]   [Full Text] [Related]  

  • 12. Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in italy by analyses based on calendar time and time since screening activation.
    Crocetti E; Buzzoni C; Falcini F; Cortesi L; De Lisi V; Ferretti S; Tumino R; Russo A; Paci E
    Breast J; 2010; 16(4):350-5. PubMed ID: 20443789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone therapy and breast cancer risk: trumping fear with facts.
    Kaunitz AM
    Menopause; 2006; 13(2):160-3. PubMed ID: 16645526
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity.
    Harvey JA; Pinkerton JV; Herman CR
    J Natl Cancer Inst; 1997 Nov; 89(21):1623-5. PubMed ID: 9362162
    [No Abstract]   [Full Text] [Related]  

  • 15. Marked regression of a nonpalpable breast cancer after cessation of hormone replacement therapy.
    Harvey SC; DiPiro PJ; Meyer JE
    AJR Am J Roentgenol; 1996 Aug; 167(2):394-5. PubMed ID: 8686614
    [No Abstract]   [Full Text] [Related]  

  • 16. Breast cancer and hormone-replacement therapy: the Million Women Study.
    Bliss JM; Gray R
    Lancet; 2003 Oct; 362(9392):1328-9; author reply 1330-1. PubMed ID: 14575984
    [No Abstract]   [Full Text] [Related]  

  • 17. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammographic changes after hormone replacement therapy in patients who have undergone breast irradiation.
    Margolin FR; Denny SR; Gelfand CA; Jacobs RP
    AJR Am J Roentgenol; 1999 Jan; 172(1):147-50. PubMed ID: 9888757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hormone replacement therapy on mammographic findings.
    Bülbül NH; Ozden S; Dayicioglu V
    Arch Gynecol Obstet; 2003 Apr; 268(1):5-8. PubMed ID: 12673467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and mammographic density.
    Kilicdag EB; Bagis T; Pourbagher A; Tarim E
    Int J Gynaecol Obstet; 2004 Jul; 86(1):56-8. PubMed ID: 15207680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.